CELG News and Press, Celgene Corporation From 09/05/19

August 27, I updated subscribers on the Bristol-Myers ( BMY ) and Celgene ( CELG ) deal. It looked very attractive. Today, it looks even more attractive to me. Here are my three reasons to buy/add; 1) Bristol-Myers made a deal with Amgen (AMGN), contingent upon FTC consent decree and closing o...

Merger activity remained unchanged last week with four new deals announced and three deals closing. Deal Statistics: New Deals: The acquisition of SRC Energy (SRCI) by PDC Energy (PDCE) for $1.7 billion in an all-stock deal. Under the terms of the agreement, SRC shareholders wil...

Amgen ( AMGN ) is one of the world’s largest pharmaceutical companies in terms of revenue and holds a $120B-plus valuation. With 17 drug categories generating annual revenue in the $20-$22B range, the company is well established, but future growth has become a concern - sales growth h...

This article is part of a series that provides an ongoing analysis of the changes made to John Paulson's 13F stock portfolio on a quarterly basis. It is based on Paulson's regulatory 13F Form filed on 08/14/2019. Please visit our Tracking John Paulson's Paulson & Company Portfolio serie...

By Breakingviews Bristol-Myers Squibb's (BMY) boss Giovanni Caforio can heave a sigh of relief. The drugmaker, valued at $76 billion at Friday's close, is stretching to buy Celgene (CELG) for almost as much again. To smooth U.S. antitrust review, it put its target's blockbuster psoriasis t...

This article is part of a series that provides an ongoing analysis of the changes made to George Soros’s 13F stock portfolio on a quarterly basis. It is based on George Soros’s regulatory 13F Form filed on 08/14/2019. Please visit our Tracking Soros Fund Management Holdings ar...

Celgene (NASDAQ: CELG ) inks an agreement with German outfit Immatics Biotechnologies GmbH  for options to develop and commercialize three T cell receptor therapies, cancer treatments similar to CAR-Ts, but different in that they recognize targets inside cancer cells rather than on t...

In June 2018, I have written my first and only article on Celgene ( CELG ) so far. In the article, I calculated an intrinsic value for Celgene of $100 (in the worst case) and ended the article with the advice to open a long position at $67, which would be a good long-term entry point. In Dec...

Introduction Many years ago I published an article on Seeking Alpha detailing how Valeant Pharmaceuticals was hoodwinking investors by substituting acquisitions for R&D and pretending this was costless by presenting pro-forma financials that ignored the substantial costs associated w...

Merger activity remained unchanged last week with four new deals announced and one deal closing. Deal Statistics: New Deals: The acquisition of DryShips ( DRYS ) in a going private transaction for $915.73 million or $5.25 per share in cash. We added DRYS as a potential deal to t...